MedPath

Good combination therapy, alpha-blocker and imidafenacin, for Nocturia of Benign Prostatic Hyperplasia with OAB in Osaka-Hokuriku study group.

Not Applicable
Conditions
Overactive Bladder
Registration Number
JPRN-UMIN000002344
Lead Sponsor
Osaka-Hokuriku maleLUTS Conference Secretariat
Brief Summary

Add-on anticholinaergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving alpha 1- blocker treatmen: a multi-centre, prospective, randomised study. A short half-life anticholinergic is suggested to be safe and effective as an add-on therapy for residual nocturia in patients with male LUTS receiving alpha 1-blocker treatment. Anticholinergic admiistration nightly could reduce the nocturnal urine volume.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Male
Target Recruitment
300
Inclusion Criteria

Not provided

Exclusion Criteria

1) Urinary retention within a year 2) Residual urine >=50mL 3) Suspect of prostate cancer 4) Treatment of any anti-muscarinic agent or beta-stimulants within a month. 5) Indwelling catheter or self intermittent urinary catherization 6) Diseases that affect nocturia (sleep apnea syndrome, Restless legs syndrome, insomnia etc.) 7) The shift work and circadian rhythm disorder, patients with irregular lifestyle 8) Bladder training conducted over the past 10 days 9) Active urinary tract infection 10) Having been given hormones or 5 alpha-reductase inhibitor within the past six months 11) Contraindication to Imidafenacin (Primary angle-closure glaucoma, urinary retention, Obstructive intestinal disease, paralytic ileus, gastrointerstinal atony, myastania gravis) 12) Judged as being unsuitable for the trial by the researcher.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1) Mean freaquency of nocturnal mictrition, 2) N-QOL, 3) Pittsburgh Sleep Quality Index)
Secondary Outcome Measures
NameTimeMethod
1) OABSS 2) IPSS&QOL 3) mean night-time urine (mean nocturnal urine volume) 4) maximum voided volume 5) residual urine volume 6) adverse events and side-effects
© Copyright 2025. All Rights Reserved by MedPath